Question to the Department of Health and Social Care:

To ask Her Majesty's Government what plans they have to rollout Ronapreve as a prophylactic preventative treatment for COVID-19.

On 20 August 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Ronapreve (casirivimab and imdevimab) as the first monoclonal antibody combination product indicated for use in the prevention and treatment of acute COVID-19 infection.

The current supply of Ronapreve is limited globally, therefore the clinical policy prioritises the most vulnerable hospitalised patients for whom this treatment will provide the most benefit, which is supported by the clinical evidence. There are no current plans to make Ronapreve available for prophylaxis. We also anticipate that further neutralising monoclonal antibody treatments will be submitted for evaluation for a marketing authorisation by the MHRA in the next few months. If approved, these could become available for community treatment or prevention use.